Investigation Report on China Glipizide Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||335237|
|出版日期||內容資訊||英文 30 Pages
|Glipizide的中國市場 Investigation Report on China Glipizide Market, 2010-2019|
|出版日期: 2015年07月10日||內容資訊: 英文 30 Pages||
2014年的中國Glipizide市場上，Pfizer以銷售額為準獲得86％的巨大佔有率，殘餘的14％的佔有率由Shandong Wanjie High-tech Co., Ltd、Yangtze River Pharmaceutical Group、Disha Pharmaceutical Group等企業分享。
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, glipizide and glimepiride are the common drugs in the class of sulfonylurea.
As the first-line drug for type 2 diabetes, glipizide belongs to the second generation of sulfonylurea and it works by stimulating insulin secretion. Developed by Pfizer, glipizide was approved by FDA to enter the market in Apr. 1994. Glipizide in the Chinese market mainly comes from Pfizer (Trade Name: Glucotrol Common Name: Glipizide Controlled Release Tablets), Disha Pharmaceutical Group (Trade Name: Dishapian Common Name: Glipizide Tablets) and Yangtze River Pharmaceutical Group (Trade Name: Qinsu Common Name: Glipizide Extended Release Tablets). Although quite a lot local enterprises produce gliclazide, they all took up a small market share.
According to CRI's market survey, in 2014, Pfizer (US) took up a market share of about 86% for sales value in China while other companies like Shandong Wanjie High-tech Co., Ltd, Yangtze River Pharmaceutical Group and Disha Pharmaceutical Group shared the rest market share. The annual sales value of glipizide stays at CNY 50-60 million during the period of 2005-2014.
The market size of glipizide is expected to stay at a certain level in the next few years in China.